GENEVA— The IGNITE study from Chinese researchers has demonstrated how plasma—and not just tissue samples—could be used to distinguish patients with non-small cell lung cancer who could benefit from EGFR-directed therapy and that significantly more Asians than Russians had anenocarcinomas with mutated epidermal growth factor receptor. Baohui Han, MD PhD—a professor and oncologist from the Shanghai Chest Hospital—gave Oncology Times reporter Peter Goodwin details from IGNITE and also explained how a partner study—looking at erlotinib therapy for lung cancer in smokers, never smokers and women—revealed that patients with stage IIIA disease can be more effectively treated.
You may also like...
Accelerated Partial Breast Irradiation for Women over 70 with Early Breast Cancer Improved Outcomes 12 May, 2015 BREAST CANCER: Intraoperative radiotherapy at the time of lumpectomy is as effective as whole breast irradiation and associated with fewer non-cancer deaths 19 Nov, 2013 ESTRO 2015 Round-up with President Philip Poortmans 3 May, 2015 ARCON Improved Quality of Life in Advanced Laryngeal Cancer: Phase-III ARCON Trial 11 May, 2015
- Previous story Circulating Free Tumor DNA—Highly Specific, Moderately Sensitive For EGFR Mutation Testing in Lung Cancer
- Next story Brachytherapy Improves Survival for Inoperable Early-Stage Endometrial Cancer
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014